الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
Inflammatory bowel disease (IBD) is comprised of two major disorders: Crohn’s diseases (CD) and ulcerative colitis (UC). Crohn’s diseases can involve any component of the gastrointestinal tract from the oral cavity to the anus and is characterized by transmural inflammation. It typically involves the ileum, ileum and cecum, or ileum and portions of or the entire colon. Ulcerative colitis affects the colon and is characterized by inflammation of the mucosal layer. Mild ileal inflammation can be seen in UC. The diagnosis and differentiation between UC and CD are based on a critical assessment of clinical features, biochemical studies, endoscopic findings, histology, and luminal imaging. These disorders have distinct pathologic and clinical characteristics but may sometimes be difficult to distinguish in cases without small bowel involvement. Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. The significance of interleukin-6 (IL-6) in patients with inflammatory bowel disease (IBD) was studied by measuring the IL-6 level in serum and colonic tissue by means of an enzyme-linked immunosorbent assay (ELISA), and by examining its localization using an immunohistochemical method. The serum IL-6 level reflected the degree of disease activity, and the extent of affected area, and was also correlated with the serum C-reactive protein (CRP) level. This study was conducted at Mansoura University Hospital aiming to compare the level of serum interleukin-6 and fecal calprotectin in inflammatory bowel diseases (IBD) patients and healthy control, and to investigate the role of both serum interleukin-6 and fecal calprotectin to assess the activity of IBD. A total of 73 cases and 17 controls were included. Cases were divided into two groups: The first group include patients with Crohn’s diseases and the second group include patients with ulcerative colitis. Further subdivision revealed four subgroups; (1) active CD, (2) inactive CD, (3) active UC, and (4) inactive UC. All cases were subjected to complete history taking, thorough physical examination, and routine radiological investigations. Endoscopy and biopsy were done for all cases. All of the enrolled patients were subjected to determination of levels of both serum interleukin-6 (IL-6) and fecal calprotectin (FC).